An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a biotech company, just announced that the U.S. Food and Drug Administration (FDA) has allowed them to start a first-in-human (Phase I) trial of a new drug called ASC35. This means they can begin testing ASC35 in people in the United States to check safety, dosing, and how the body handles the drug. The drug is aimed at treating obesity and is given by injection under the skin once a month. ASC35 is described as a “dual peptide agonist” that targets GLP-1 and GIP receptors. In plain terms: it’s a small protein-like drug that copies signals normally made in the gut after eating. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are two natural hormones that influence appetite, how full you feel, and blood sugar control. Drugs that mimic GLP-1 are already used for diabetes and weight loss (think Ozempic or Wegovy). ASC35 aims to hit both of those hormone pathways at once and is designed to be long-acting so one shot could last a month. The announcement is about regulatory clearance to begin human testing, not about clinical results. Phase I studies typically enroll a small number of healthy volunteers or people with the target condition and focus on safety, tolerability, and finding the right dose. From this notice we don’t know any results, how many people will be in the trial, or whether it works better than existing medicines. So, at this stage there’s no evidence yet that ASC35 is effective for weight loss—only that the company can now legally and formally test it in humans in the U.S. Why this matters is practical: monthly dosing could be more convenient than the weekly injections used by current GLP‑1 drugs. If a dual-action drug works well and is safe, it might improve weight loss or blood-sugar control for people with obesity or diabetes, and a once-a-month schedule could make it easier for patients to stick with treatment. Investors, patients, and clinicians will watch closely because new options can shift standards of care and accessibility. Important caveats: Phase I is early and mainly checks safety, not long-term benefit. Many drugs that enter human trials never make it to market because of side effects or lack of effectiveness. Dual agonists may have side effects similar to current drugs—nausea, vomiting, or digestive upset—and long-term risks aren’t known yet. Also, regulatory clearance to test a drug is not the same as approval to prescribe it; extensive additional trials will be required. Bottom line: ASC35 is now entering human testing in the U.S., which is a first step, not proof that it will become a safe or effective monthly obesity treatment.
Source: PR Newswire